BR112022013577A2 - Anticorpos pfgarp para matar parasitas da malária plasmodium falciparum e proteger contra infecções e doenças severas - Google Patents

Anticorpos pfgarp para matar parasitas da malária plasmodium falciparum e proteger contra infecções e doenças severas

Info

Publication number
BR112022013577A2
BR112022013577A2 BR112022013577A BR112022013577A BR112022013577A2 BR 112022013577 A2 BR112022013577 A2 BR 112022013577A2 BR 112022013577 A BR112022013577 A BR 112022013577A BR 112022013577 A BR112022013577 A BR 112022013577A BR 112022013577 A2 BR112022013577 A2 BR 112022013577A2
Authority
BR
Brazil
Prior art keywords
pfgarp
infections
antibodies
protect against
plasmodium falciparum
Prior art date
Application number
BR112022013577A
Other languages
English (en)
Inventor
Kurtis Jonathan
K Raj Dipak
Das Mohapatra Alok
Zuromski Jenna
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of BR112022013577A2 publication Critical patent/BR112022013577A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS PfGARP PARA MATAR PARASITAS DA MALÁRIA PLASMODIUM FALCIPARUM E PROTEGER CONTRA INFECÇÕES E DOENÇAS SEVERAS. São fornecidos neste documento métodos, composições e kits para prevenir e tratar a malária. Também estão incluídos neste documento kits para prevenir e tratar a malária.
BR112022013577A 2020-01-10 2021-01-11 Anticorpos pfgarp para matar parasitas da malária plasmodium falciparum e proteger contra infecções e doenças severas BR112022013577A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959851P 2020-01-10 2020-01-10
PCT/US2021/012961 WO2021142445A1 (en) 2020-01-10 2021-01-11 Antibodies to pfgarp kill plasmodium falciparum malaria parasites and protect against infection and severe disease

Publications (1)

Publication Number Publication Date
BR112022013577A2 true BR112022013577A2 (pt) 2022-09-13

Family

ID=76788346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013577A BR112022013577A2 (pt) 2020-01-10 2021-01-11 Anticorpos pfgarp para matar parasitas da malária plasmodium falciparum e proteger contra infecções e doenças severas

Country Status (5)

Country Link
US (2) US11692026B2 (pt)
EP (1) EP4087870A4 (pt)
BR (1) BR112022013577A2 (pt)
CA (1) CA3164090A1 (pt)
WO (1) WO2021142445A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174992A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
EP2785370B1 (en) 2011-12-02 2021-07-21 Rhode Island Hospital Vaccine for falciparum malaria
ME02928B (me) 2012-02-24 2018-04-20 Abbvie Stemcentrx Llc Dll3 modulatori i metode upotrebe
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
WO2018165720A1 (en) 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
US20220265806A1 (en) 2018-06-06 2022-08-25 Albert Einstein College Of Medicine, Inc Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same

Also Published As

Publication number Publication date
US11692026B2 (en) 2023-07-04
EP4087870A1 (en) 2022-11-16
US20240141028A1 (en) 2024-05-02
CA3164090A1 (en) 2021-07-15
US12037386B2 (en) 2024-07-16
US20210230258A1 (en) 2021-07-29
WO2021142445A1 (en) 2021-07-15
EP4087870A4 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
DOP2019000201A (es) Compuestos inhibidores del vih
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
CL2017002567A1 (es) Composiciones para modular la expresión de c9orf72
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
BR112018016054A2 (pt) composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
EA201791258A1 (ru) Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
BR112022014700A2 (pt) Sars-cov-2 desotimizado e métodos e usos do mesmo
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
AR102657A1 (es) Composición para tratar telas
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
BR112018071592A2 (pt) inibidores de erbb e usos dos mesmos
CL2021003169A1 (es) Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas
EA202193111A1 (ru) Композиции и способы для лечения рака
TN2019000106A1 (en) Novel compounds for treating parasitic disease
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
PH12018501646A1 (en) Compositions and methods for treating infections
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
BR112018076619A2 (pt) composições antimalariais e usos das mesmas
UY39504A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión